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Cancer is a multistep disease driven by the activation of specific oncogenic pathways
concomitantly with the loss of function of tumor suppressor genes that act as sentinels
to control physiological growth. The conservation of most of these signaling pathways
in Drosophila, and the ability to easily manipulate them genetically, has made the fruit
fly a useful model organism to study cancer biology. In this review we outline the basic
mechanisms and signaling pathways conserved between humans and flies responsible
of inducing uncontrolled growth and cancer development. Second, we describe classic
and novel Drosophila models used to study different cancers, with the objective to
discuss their strengths and limitations on their use to identify signals driving growth cell
autonomously and within organs, drug discovery and for therapeutic approaches.
Keywords: Drosophila cancer modeling, cancer biology, oncogene, tumor suppressor, tissue growth, signaling,
metabolism, therapeutic approaches
INTRODUCTION
The fruit fly, Drosophila melanogaster, is used as a model organism to study disciplines ranging
from fundamental genetics to the development of tissues and organs. Drosophila genome is 60%
homologous to that of humans, less redundant, and about 75% of the genes responsible for human
diseases have homologs in flies (Ugur et al., 2016). These features, together with a brief generation
time, low maintenance costs, and the availability of powerful genetic tools, allow the fruit fly to
be eligible to study complex pathways relevant in biomedical research, including cancer. Indeed,
publications that use flies to model cancer have exponentially increased in the last 10 years, as
shown in the graph of Figure 1, suggesting the relevance of this model to cancer research.
In this review we first describe the basic biological mechanisms responsible for uncontrolled
growth conserved between humans and flies. We placed a particular emphasis on the
characterization of epithelial tumors from most studied models (gut and brain), to novel
approaches for studying tumor-induced angiogenesis, prostate, thyroid and lung cancers, with the
goal to discuss their strengths and limitations. In the second part, we analyze few physiological
mechanisms that uncover potential non-autonomous mechanisms controlling growth, including
the relation between the immune cells (macrophages) and the growth of epithelial cells, or the
function of lipid metabolism in cancer growth. Finally, we discuss how Drosophilamodels are used
to find novel interesting therapeutic approaches.
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FIGURE 1 | Graph representing the number of publications in PubMed found
with the terms “Drosophila cancer model,” in the last 48 years.
PROPERTIES OF EPITHELIAL
CANCER CELLS
Cancer cells are characterized by unrestrained proliferation
that results from defects in signaling driving cellular growth,
apoptosis and changes in metabolic pathways. At cellular level,
the hyperproliferative status of cancer cells is mainly due to
the activation of growth signals induced by proto-oncogenes
(e.g., the RAS/RAF/MAPK axis), which function downstream
of receptor signaling cascades, and are deregulated in 25%
of human tumors (Samatar and Poulikakos, 2014). Tumor
cells escape the anti-proliferative effect of tumor suppressor
genes, such as RB (retinoblastoma-associated) and TP53 genes
(Duronio and Xiong, 2013), through mutations in these genes,
which result in uncontrolled growth (Hanahan and Weinberg,
2000, 2011; Hariharan and Bilder, 2006). Apoptotic cell death
represents another physiological mechanism to maintain cellular
homeostasis, and cancer cells have developed strategies to evade
apoptosis, i.e., by increasing the activity of anti-apoptotic genes
(Bcl-2, Bcl-xL, Bcl-w) and of pro-survival factors (Igf-1, Igf-
2) or by downregulating the action of pro-apoptotic genes
(Bax, PUMA, Bin) (Hanahan and Weinberg, 2011). Another
characteristic of cancer cells is the reactivation of telomerase,
present in 90% of human cancers, that allows them to replicate
unlimitedly (Kumar et al., 2016).
Cancer cells also exhibit alterations in metabolic pathways
that contribute to their survival. Rapidly proliferating cells have
a high metabolic rate and suffer from low oxygen conditions
(hypoxia). In epithelial tumors, this condition triggers the so-
called angiogenic “switch” where the quiescent vascular network
is induced to proliferate by the secretion of pro-angiogenic
factors, such as VEGF (Vascular Endothelial Growth Factor) and
FGF (Fibroblast Growth Factor) (Hida et al., 2018), allowing the
formation of new vessels that penetrate into the tumor mass to
supply oxygen and nutrients (Carmeliet and Jain, 2011). Cancers
cells also exhibit a metabolic switch where they reprogram their
metabolism to use an alternative and less abundant anabolic
pathway to sustain their growth. In particular they switch from
oxidative phosphorylation to anaerobic glycolysis, where glucose
is used to produce lactate, through a process called the “Warburg
effect” (Pavlova and Thompson, 2016; Vander Heiden and
DeBerardinis, 2017). This metabolic switch is not yet completely
characterized but is supported by the activation of oncogenes,
including Myc that also activates glutaminolysis to fuel the TCA
cycle with anaplerotic reactions to produce the intermediates
necessary for cellular biosynthesis (Hsieh and Dang, 2016).
The last stage of tumorigenesis is represented by the invasive
and metastatic capabilities of tumor cells to disrupt the apical-
basal cell polarity, a process that is associated with the
downregulation of cell-cell contact molecules and the release
of metalloproteases (MMP1), lytic enzymes that degrade the
extracellular matrix (ECM) allowing tumor cells to escape and
colonize an environment that suites them and to acquire new
oncogenic properties (Massague and Obenauf, 2016; Lambert
et al., 2017). A variety of studies are now focused on how the
tumor micro environment (TME), a specific niche composed of
fibroblasts, lymphocytes and immune cells, that may shape pre-
cancer cells for their progression into cancer cells and it may
select the development of metastasis (Massague and Obenauf,
2016). Emergent evidence suggests also a key role for non-
autonomous signals released by the cells composing the niche,
particularly from cancer-associated fibroblasts (CAFs), that are
essential to support the growth of cancer cells in this “new”
metabolic environment (Lambert et al., 2017).
CANCER MODELING IN DROSOPHILA
Most of the signaling pathways controlling cell growth and
invasion in mammals have a conserved function in flies allowing
their modulation into models that mimic tumor’s biology in
a simple model organism like Drosophila (Millburn et al.,
2016). The combination of genetic screens with the availability
of powerful recombination techniques enabled also a rapid
characterization of the primary function of conserved oncogenes
and of tumor suppressor genes in a whole animal (Sonoshita
and Cagan, 2017). In addition, recent studies using Drosophila
imaginal discs explored the mechanisms that govern growth in
epithelial tumors and their interaction with the local TME and
stromal cells, including some steps in the recruitment of the
immune cells (macrophages) to the tumor mass (Herranz et al.,
2016; Muzzopappa et al., 2017).
EPITHELIAL TUMORS IN DROSOPHILA
About 90% of human cancers are of epithelial origin (Hanahan
and Weinberg, 2000). Epithelial tissues are characterized by
a specific cell architecture composed of junctions and apical
and baso-lateral membrane domains that are crucial for the
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maintenance of cell-physiological functions. Loss of cell adhesion
and cell polarity, with an increase of cell motility, are indeed
characteristic early cancer traits. In this context, Drosophila
larval imaginal discs are a monolayer epithelium that is limited
apically by a squamous epithelium (peripodial membrane) and,
basally to the notum, by a layer of myoblasts embedded in
Extracellular Matrix, and constitute a perfect system in which
to model the onset of epithelial cancer progression. These
larval organs are indeed morphologically and biochemically
comparable to mammalian epithelia (Wodarz and Nathke,
2007). Moreover, the prominent signaling pathways that regulate
growth in humans are conserved in the fruit fly (Figure 2),
allowing the use of this animal model to examine the hallmarks
of cancer (St. Johnston, 2002). During the last few years, the
imaginal wing and eye discs have been used successfully to
study tumor growth and invasion, to investigate the function
of cancer genes, and to perform chemical screenings (Tipping
and Perrimon, 2014). The imaginal discs also represent an
excellent model to analyze oncogenic cooperation: thanks to the
use of the MARCM system (Lee and Luo, 1999), it is feasible
to induce simultaneously in single cells mutations in tumor
suppressor genes (e.g., mutations in cell polarity genes andHippo
pathway components and interactors) and oncogenic activating
mutations, or to overexpress specific genes (e.g., EGFR, Ras, Myc,
Yorki), resulting in tissue overgrowth, alteration of the normal
tissue architecture, disruption of the basement membrane, and
invasive/metastatic behavior (Brumby and Richardson, 2003;
Pagliarini and Xu, 2003; Wu et al., 2010).
Marks of Alteration in Epithelial Cells
Loss of Cell Polarity
Cellular junctions and a proper apical-basal cell polarity
are fundamental for the maintenance of epithelial tissue
architecture and function. During early cancer stages, tissues
lose these properties and cells subvert their normal growth
rate and acquire invasive and migratory behaviors (Wodarz
and Nathke, 2007; Bryant and Mostov, 2008). In Drosophila,
three complexes establish and maintain epithelial polarity:
the Crumbs/Stardust/PATJ/Bazooka, the Par6/aPKC (atypical
protein kinase-C) and the Scrib/Dlg/Lgl (Scribble/Discs
large/Lethal giant larvae) complexes, which are respectively
placed at the apical, subapical and baso-lateral membrane
domains. Alterations in these proteins provoke continued
cell proliferation, loss of differentiation and complete loss of
tissue architecture, resulting in neoplastic overgrowth (Bilder,
2004; Grzeschik et al., 2010; Johnson and Halder, 2014). lgl
was the first neoplastic tumor suppressor gene discovered
in Drosophila and its loss leads to an abnormal growth of
the imaginal structures and the larval brain. In addition, lgl
mutant tissues, and tissues bearing dlg or scrib mutation, have
the ability to form secondary tumors in the thorax, brain,
wings, muscles, intestine and ovaries (Woodhouse et al., 1998).
The loss of cell polarity impacts cell proliferation through
the deregulation of the Hippo (Hpo) pathway, a signaling
cascade involved in organ size maintenance (Lu et al., 2010).
It is not yet fully known how lgl activity interacts with the
Hpo cascade, but it was observed that its downregulation
FIGURE 2 | Major pathways converging on uncontrolled growth in Drosophila
epithelial cells. The signaling pathways outlined confer growth, migration and
invasive capabilities to epithelial cells both in vertebrates and flies. Models that
mimic the growth of epithelial cancer cells and their ability to undergo
metastasis in Drosophila have been established by inducing the cooperation
between oncogenes (RED) like the active form of Ras (RasV12) together with
the loss of function of cell polarity genes (GREEN) (Brumby and Richardson,
2003; Pagliarini and Xu, 2003). Alteration of cell polarity with the
downregulation of the SWH (Salvador-Hippo-Warts) pathway, together with
RasV12, triggers downstream events, including activation of the MAPK
signaling that stabilize Myc protein (Galletti et al., 2009) resulting in robust
cellular growth. Activation of the JNK signaling, with the concomitant loss of
cell polarity, induces metalloproteases (MMP-1) and confers to the epithelial
cells the distinct characteristics of migration and invasion, hallmarks of tumor
growth (Uhlirova et al., 2005; Igaki et al., 2006; Ma et al., 2017).
up-regulates cell cycle genes (such as Cyclin E and E2F1)
(Grzeschik et al., 2007) and permits the nuclear translocation
of Yorkie (Yki), the downstream effector of the Hippo pathway,
causing the activation of its target genes, including MYC,
that was found to be important for the growth of lgl mutant
clones in a competitive environment (Froldi et al., 2010). In
humans, two lgl homologs have been discovered, HUGL-1
and HUGL-2, with HUGL-1 rescuing all the defects of the
fly lgl mutant (Grifoni et al., 2004). HUGL-1 loss of function
has been associated with a series of human malignancies
(Schimanski et al., 2005; Grifoni et al., 2007; Lu et al., 2009).
Finally, while the human genome encodes for only one homolog
of the tumor suppressor scrib, a number of homologs are
known for dlg which have been implicated in different types of
cancer (Halaoui and McCaffrey, 2015).
Growth Signaling
The Salvador-Warts-Hippo (SWH) tumor suppressor pathway
was discovered first in Drosophila as a regulator of organ
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size (Pan, 2010; Yu et al., 2015) and later in humans, where
it was found to be fundamental in the regulation of cancer
growth (Harvey et al., 2013). The physiological activation
of the Hippo (HPO) kinase, (MST1/2 in human) (Harvey
et al., 2003) consists in the phosphorylation of Warts (WTS),
(LATS1/2 in human) (Genevet et al., 2010; Yu et al., 2010)
and in the activation of the phosphorylated core complex,
that includes Salvador (SAV in human) (Tapon et al., 2002)
and Mob/MATS, that in turn, phosphorylate Yki (YAP/TAZ
in humans) (Oh and Irvine, 2008). Phosphorylated Yki is
sequestered and degraded in the cytoplasm, resulting in the
inhibition of its nuclear transcriptional activity and oncogenic
function (Harvey et al., 2013). Upstream, the Hippo cascade
is regulated by components of cell junctions, including cell
adhesion molecules such as Merlin, a homolog of the human
Neurofibromatosis Type 2 (NF2) (Genevet et al., 2010; Yu
et al., 2010), which acts as tumor suppressor; the cadherin
Fat in complex with Dachsous; and by cell polarity regulators
such as Crumbs (Robinson et al., 2010; Harvey et al., 2013).
Alterations in the composition of the core proteins (HPO,
WTS, SAV, MATS) of the pathway trigger Yki translocation into
the nucleus that binds tissue-specific partners and induces the
expression of its target genes, among them: CyclinE, dIAP1 and
MYC (Harvey et al., 2003; Pantalacci et al., 2003; Neto-Silva
et al., 2010; Ziosi et al., 2010). This articulated system is also
tightly regulated by other signaling pathways: for example, in
the Drosophila imaginal wing disc, Lgl or aPKC deregulation
results in JNK activation to promote Yki nuclear translocation
via phosphorylation of Ajuba (Jub), an upstream regulator
of the cascade that binds to and inhibits Wts kinase activity
(Sun and Irvine, 2013). In addition to the regulation of cell-
cell interaction signals, components of the Hippo pathway
have been found to be sensitive to mechanical stress (Panciera
et al., 2017). This mechanotransduction function is critical
in the control of physiological pathways, and its deregulation
may contribute to the abnormal cell behavior in diseases
such as cancer, where the cells in the tumor have to sustain
physical forces generated by tissue overgrowth. Interestingly,
this last function has shown differences in the behavior of Yki
between human and flies: indeed, in Drosophila the Yki protein
does not respond to integrin stimulation, while in mammals
integrin signaling promotes YAP/TAZ activity. One possible
explanation for this different behavior may be that the N-
terminus of Yki is missing a domain necessary to bind PDZ-
containing proteins, which is found in its human counterpart
YAP, and is necessary for the activation of the integrin-Src
adhesion branch of the pathway (Elbediwy and Thompson,
2018). However, an interesting and potential explanation for
this difference comes from a comparative analysis of the
Yki protein and the evolution of the different epithelia: this
analysis outlines how in Drosophila the apical membrane of
the columnar epithelium is well differentiated in its function to
activate the Hippo pathway, whereas in mammals the multilayer
of cells lacks a functional apical domain, and the activation
of YAP/TAZ relies on the activation/signal from the integrin
adhesion pathways of the stem cells on the basal layer of the
epithelium (Elbediwy and Thompson, 2018).
The RAS/RAF/ERK signaling cascade is one of the most
conserved pathways in all organisms, including Drosophila. This
pathway is part of the MAP kinase signaling that, in addition to
ERK1/2, also includes JNK1/2/3, p38/MAPK, and ERK5, which
mainly respond to stress activators (Morrison, 2012). Highly
conserved in flies, ERK1/2 are activated by growth factors such
as EGF or FGFs. These ligands bind to receptor tyrosine kinases
(RTKs) to activate downstream signaling, in particular its core
complex, which is represented by the guanidine exchange factor
Son of Sevenless (SOS) that, in turn, activates the small G
proteins RAS on the cell membrane. This leads to RAF activation
and to the formation of the complex with the kinase D-Sor
also called MAPKK or MEK that, upon phosphorylation of
Rolled, the fly homolog of MAPK or ERK kinases, induces
the activation of its final targets (Shilo, 2014). ERK in flies
has much fewer targets than those described in vertebrates, the
most common being the ETS-domain protein Pointed (Pnt). In
particular PntP2, needs to be phosphorylated for its activation
and is the principal activator of transcription downstream of
many RTKs, and PntP1 is transcriptionally induced by MAPK
(Shilo, 2014). A second transcriptional repressor is Capicua (Cic),
an HMG box-containing protein highly conserved in vertebrates
(Simon-Carrasco et al., 2018). Interestingly, in the last couple
of years, this protein was found to possess oncogenic properties
and be overexpressed in many tumors (Simon-Carrasco et al.,
2018). In addition, Cic activity regulates co-target genes upon
Yki activation, placing this protein at the crossroads of RTKs and
SWH pathways (Simon-Carrasco et al., 2018).
Even though MAPK targets in Drosophila are less abundant
than in mammals, its activation and translocation to the nucleus
results in a growth phenotype mimicking a few characteristic
steps of growth in tumor cells (Brumby et al., 2011). Activation
of Ras is considered a cancer distinctive trait both in Drosophila
and humans, and it represents one of the strategies to model
human cancer in flies. In Drosophila there are three Ras genes
but only Ras1 has functional homology with mammalian RAS.
In the epithelial cells of the wing imaginal disc, Ras1 activation
triggers hyperproliferation but also determines cell fate (Prober
and Edgar, 2000). Ras activation is at the crossroads of other
growth factor signaling cascades: recently, a link to Hpo function
was shown in Drosophila epithelial cells, where Ras activation
was able to induce the tissues to switch from a pro-differentiative
to a pro-growth program by modulating SWH’s transcriptional
output (Pascual et al., 2017). Ras increases cell proliferation also
through the transcriptional regulation of growth factors and
their receptors. For example, it helps promote angiogenesis-like
mechanisms in tracheal development through secretion of the
FGF/EGFR molecules (Petit et al., 2002; Grifoni et al., 2015); its
activation stabilizes pro-growth signals including MYC (Prober
and Edgar, 2000), and inhibits pro-apoptotic molecules like
Hid (Bergmann et al., 1998). Because of all these functional
homologies to human RAS, its activation in Drosophila is
considered a good method to establish models that mimic
tumor growth.
The JNK Signaling Pathway is activated mainly by oxidative
stress, producing reactive oxygen species (ROS), and by Eiger,
the Drosophila homolog of TNF-α. Its function is variable and
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depends also on the cellular environment: it can indeed induce
cell proliferation and migration, but its major role is to induce
apoptosis (Igaki, 2009). The signaling core is characterized
by Hemipterus/Hep (JNKK) (Glise et al., 1995), Basket/Bsk
(JNK) (Stronach, 2005) and the AP-1 complex, that functions
as negative feedback by up-regulating the expression of the
Puckered phosphatase (Martin-Blanco et al., 1998). The AP-1
complex is composed of Fra (Fos-Related Antigen) and dJun
(Drosophila Jun) and is the final effector of the cascade (Kockel
et al., 2001). Upstream Hep is phosphorylated by many JNKK
kinases (Tak1-12, Mekk1, Ask1, Slpr) and can also be activated
by different indirect stimuli (e.g., RAS, JNKKKK/Msn, and
Eiger). Cell death is induced by the expression of the pro-
apoptotic genes hid, reaper and grim, whose activity inhibits
the pro-survival protein dIAP1 (Weston and Davis, 2007).
In Drosophila cancer cells, the JNK pathway plays a dual
role, by suppressing or promoting growth depending on the
context (Brumby and Richardson, 2003; Uhlirova et al., 2005;
Cordero et al., 2010). lgl, scrib, and dlg mutant cells undergo
JNK-mediated apoptosis resulting in a mechanism of tumor
suppression (Brumby and Richardson, 2003; Uhlirova et al.,
2005; Igaki et al., 2006). On the contrary, in tumor cells
with active RAS, apoptosis is blocked and JNK signaling acts
as a tumor promoter transcribing genes involved in growth
and invasion such as MMP1 (Igaki et al., 2006; Uhlirova and
Bohmann, 2006). The overexpression of activated RAS together
with Hep (rasv12hepwt) gives cells invasive and metastatic
abilities, highlighting how these pathways converge to induce
transformation in epithelia.
The PI3K/Target of rapamycin (TOR) signaling pathway
is a highly conserved key regulator of growth. The binding
of insulin-like peptides (ILPs) (fly’s insulin) to the receptor
(InR) results in the phosphorylation of chico/IRS1-4, and the
production of phosphatidylinositol-3, 4,5-triphosphate (PIP3) by
PI3K, a reaction that is counteracted by the lipid phosphatase
PTEN (Grewal, 2009). PIP3 recruits several Ser/Thr kinases
to the plasma membrane, including Akt/PKB and PDK1 (3′-
phosphoinosite-dependent protein kinase-1), while its activation
results in the inhibition of Glycogen Synthase Kinase-beta
(GSK3-β), a conserved kinase that not only controls energy
metabolism by inactivation of Glycogen Synthase, but also
regulates Wnt signaling by controlling β-catenin/armadillo (Xu
et al., 2009) and Myc stability (Bellosta and Gallant, 2010).
Activation of Akt also inhibits Tuberous Sclerosis Complex
1 and 2 (TSC1/2), a tumor suppressor binary complex that
negatively regulates Rheb, a GTPase upstream of TOR kinase
responsible for the activation of TORC1. TOR is found in two
complexes: TORC1, which includes Raptor and LST8 adaptor
molecules, is sensitive to amino acids and is inhibited by
rapamycin; and TORC2, that is composed of LST8 and Rictor
adaptor molecules, and does not respond to amino acids or
rapamycin (Saxton and Sabatini, 2017). Activation of TORC1
results in phosphorylation of ribosomal protein kinase p-70-
S6 (S6K) and of eukaryotic translation initiation factor 4E-
binding protein-1(4E-BP1), thereby triggering protein synthesis
and initiation of translation. Insulin and TOR activities are also
balanced by a negative feedback mechanism that is activated
when S6K is hyper-activated to counteract insulin activity. Under
this condition, S6K phosphorylates IRS1-4/chico triggering its
internalization and subsequent proteasomal degradation. This
feedback mechanism is reduced in pathological conditions, such
as the Tuberous Sclerosis Complex syndrome (TSC), where cells
carrying tsc1 or tsc2 mutations display an abnormal increase in
size and exhibit constitutive phosphorylation of S6K (Saxton and
Sabatini, 2017). As members of PI3Ks and TOR signaling are
frequently activated in human tumors, they are attractive targets
for cancer treatment.
Myc and Cell Competition
MYC is one of the most studied oncogenes, and its misexpression
is associated with various tumor types including meningioma,
Burkitt’s lymphoma, medulloblastoma and hepatocellular
carcinoma (Hsieh and Dang, 2016).DrosophilaMyc is the sole fly
member of the family of transcription factors that in mammals
is composed of three genes (N-, L-, and c-MYC) (Gallant et al.,
1996; Schreiber-Agus et al., 1997). Hypomorphic alleles of myc
in flies are developmentally delayed and show a reduction in cell
size resulting in smaller flies (hence the name of the mutant as
diminutive = small) (Johnston et al., 1999), while null mutants
die during larval stage (Pierce et al., 2004). Notably, ubiquitous
expression of myc increases cell mass resulting in enrichment
of genes encoding components of the nucleolus and of the
ribosome; this evidence, concomitantly with Myc’s ability to
indirectly stimulate RNA pol I and III (Grewal et al., 2005;
Hulf et al., 2005; Orian et al., 2005), contribute to revealing
its role in the control of ribosomal biogenesis, thus mass and
size. Myc activity is finely regulated, and while its expression is
required at physiological levels during development, an excess
of its activity triggers autonomous cell death and unbalanced
growth (Grifoni and Bellosta, 2015). Therefore, Myc is strictly
controlled both transcriptionally and post-translationally, where
its protein stability is controlled by phosphorylation events
downstream of RAS/ERK and GSK3β kinases with a signaling
conserved in flies and mammals (Galletti et al., 2009; Parisi
et al., 2011). Myc regulation of the cellular metabolic milieu is
highly similar in Drosophila to the regulation found in tumor
cells (DeBerardinis et al., 2008), indeed it was shown that in
cells undergoing to a metabolic stress (starvation or competitive
environment), expression of Myc switched their metabolism
to increase glycolysis, glutaminolysis (Parisi et al., 2013; de la
Cova et al., 2014; Hsieh et al., 2015), or lipid metabolism to favor
survival by inducing autophagy (Parisi et al., 2013; Paiardi et al.,
2017). Fascinatingly, these evolutionary functions of Myc to
control mass and metabolism, resulted in the selective advantage
of growth of epithelial cells described as cell competition and
characterized in the monolayer epithelia composing Drosophila’s
imaginal discs (Johnston, 2014). Briefly, cells expressing Myc
create a competitive environment and they grow at the expense of
wild-type cells that are killed by non cell-autonomous apoptosis
(de la Cova et al., 2004; Moreno and Basler, 2004). Myc cells
thus behave as “winners” and they are able to repopulate the
space of the dying “loser” cells that are killed by unidentified
Myc-dependent mechanisms (Johnston, 2014). Myc-induced
cell competition was also shown to be necessary in vertebrates
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to eliminate unfit cells (losers) during early embryogenesis
(Claveria and Torres, 2016). More recently, evidence that
sustains a central role for Myc-induced cell competition in the
early steps of tumor formation have shown Myc present at high
levels in cells surrounding the tumor near dying cells, potentially
allowing the winner cells to expand and to eliminate the
surrounding wild-type cells, thus establishing the first evidence
of Myc involved in a tumor growth competitive environment
(Johnston, 2014; Di Giacomo et al., 2017). Another form of cell
competition is regulated by cell polarity genes (lgl, scrib, dlg)
and by endocytic genes (such as Rab5). Cells mutant for these
genes behave as losers and were eliminated by wild-type cells
(Brumby and Richardson, 2003; Menendez et al., 2010); notably
the expression of oncogenes in those loser clones provided
them with super-competitive characteristics, i.e., lgl mutant
cells over-expressing MYC send death signals to the adjacent
wild-type proliferating cells (Froldi et al., 2010), suggesting the
presence of another mechanism of cell competition driven by
different growth forces working in combination with cell polarity
genes and oncogenic signals.
ORGANOTYPIC DROSOPHILA
CANCER MODELS
Gut Cancer
Similar to mammalian counterparts, the Drosophila adult gut is
specialized in the digestion of food, the absorption of nutrients,
and for controlling the defense response against infection (Tian
et al., 2018). Based on these distinct functions, the Drosophila gut
is composed of three parts: foregut, midgut, and hindgut. Among
them, the midgut has a distinct architecture that resembles the
digestive tract of vertebrates. The epithelium is a monolayer that
is replenished by Intestinal Stem Cells (ISCs) that differentiate
to either enteroblasts (EB) or pre-enteroendocrine cells (pre-
EE), that then differentiate into absorptive enterocytes (EC)
or secretory enteroendocrine cells (EE). Thanks to significant
similarities in the physiology between the Drosophila gut and
the intestine of vertebrates (Apidianakis and Rahme, 2011),
Drosophila adult midgut epithelium has been used to study
the contribution of signaling pathways (i.e., EGFR, Notch,
Hedgehog, and Wg/Wnt) to Intestinal Stem Cells (ISCs) renewal
(Jiang and Edgar, 2009; Biteau and Jasper, 2011; Jiang et al., 2011).
In vertebrates, the majority of sporadic cases of colorectal
cancer and familial adenomatous polyposis (FAP) cancer
syndrome are associated with activation of Wnt signaling (Bienz
and Clevers, 2000). In humans, abnormal expression of Wnt in
ISCs promotes adenoma formation, while deletions in mouse
ISCs of the tumor suppressor adenomatous polyposis coli gene
APC triggers the initial step of colon-adenoma formation (Barker
et al., 2009), underlying the relevance of both mutations in this
malignancy. In Drosophila, loss of the Apc gene, leads to the over
proliferation of ISCs in the gut, resulting in loss of epithelial cell
polarity, hyperplasia and epithelial overgrowth resembling that
of intestinal adenomas induced by the loss of APC (Yu et al.,
1999). Remarkably, the over-proliferation of the Apc −/− cells
was rescued by lof mutation of Ras (Wang et al., 2013). On
the contrary Apc−/− cells expressing an active form of Rasv12
showed a malignant transformation including loss of cell polarity
and invasive phenotype, highlighting the conserved functional
cooperation between RAS and APC in controlling proper growth
in the gut. In Drosophila, intestinal progenitors mutant for the
Apc gene expand at the expense of the surroundingwild-type cells
that die by apoptosis; because of this behavior these cells have
been defined as “super-competitors” (Suijkerbuijk et al., 2016).
Apc mutant cells exhibit higher Yki/YAP activity and increased
JNK signaling, that was also detected at the border between
Apc−/− and wild-type cell; moreover, inhibition of apoptosis
prevented Apc mutant cells from further expansion, suggesting
that a competitive behavior in these cells is controlling Apc
dependent tumor growth (Suijkerbuijk et al., 2016).
The JNK-Wg signaling is important to control the physiology
and regeneration of intestinal cells, as ISCs damage leads to an
overactivation of the JNK pathway and an increase in Wg ligand
(Biteau et al., 2008; Cordero et al., 2012b). Wg activity in the
enterocytes (ECs) indirectly drives the expansion of the ISCs by
upregulating the JAK-STAT ligands Upd2 and Upd3, acting non-
autonomously on ISCs proliferation (Tian et al., 2018).Moreover,
activation of Wnt drives Myc upregulation in ISCs leading to
non-autonomous upregulation of Upd3 in the ECs (Cordero
et al., 2012a). Similarly, loss of Apc1 in the midgut (ISCs) also
results in JAK-STAT and EGFR pathway hyper-activation, and
their removal suppresses the intestinal hyperplasia resulting from
Apc1 loss, revealing an underlying conserved signaling between
flies and mammals that controls ISCs proliferation and gut
homeostasis (Cordero et al., 2012a).
Another aggressive oncogene that is hyper-activated upon
Apc loss, in mouse and human intestinal adenomas is the non-
receptor tyrosine kinase c-Src (Yeatman, 2004). This proto-
oncogene is amplified or activated in more than 20% of human
tumors, and its activity has been demonstrated to play a central
role in the formation of colorectal cancer (CRC). In mice,
expression of c-Src increases in the proliferative progenitor
cells of the “cripta” favoring hyperplastic adenoma formation
(Cordero et al., 2014). In Drosophila the expression of c-Src
orthologs (Src42A and Src62B) induces proliferation of the ISCs
cells in wild-type animals, and reduction of their expression
is sufficient to inhibit ISCs’ hyper-proliferation of Apc mutant
cells (Cordero et al., 2014). Notably, these results recapitulate
an important part of the function of mammalian c-Src in the
progenitor cells of the intestine during homeostasis and adenoma
formation, suggesting a conserved role of this gene in flies in
controlling proper ISCs proliferation.
Recently, Drosophila was also used to generate multigenic
models of colon cancer using data from patients from The
Cancer Genome Atlas. Interestingly, the outcomes of these
models mimicked important properties of human cancers,
and can be explored and used in chemical screens to find new
combinations of cancer-relevant drugs (Bangi et al., 2016).
Studies, using Drosophila models, to characterize intestinal
human pathophysiology, revealed the high conservation
between these species of the mechanisms underlaying
colorectal tumorigenesis (Christofi and Apidianakis, 2013),
and further revealed also the mechanisms that control
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the processes leading to bacterial-mediated inflammation
(Lemaitre and Hoffmann, 2007).
Brain Cancer
Meningioma are the most common intracranial tumors (Claus
et al., 2005; Rogers et al., 2015) and frequently linked with
mutations in the PI3K catalytic subunit p110α isoform encoded
by the gene (PI3KCA), or in the v-akt murine thymoma viral
oncogene homolog 1 (AKT1) gene. Complex interactions were
found between members of the PI3K/AKT/mTOR pathway
and MAPK-, JAK/STAT, and Notch-1-mediated pathways that
contribute to meningioma progression (El-Habr et al., 2014).
Increased risk of meningiomas was associated also with
neurofibromatosis type II syndrome, where mutations within the
tumor suppressor gene Suppressor of fused (SUFU) was associated
with hereditary meningiomas (Aavikko et al., 2012) and with
medulloblastomas (Taylor et al., 2002). In Drosophila SUFU
regulates Hedgehog (Hh) signaling (Ohlmeyer and Kalderon,
1998), with a similar function in humans, where loss of SUFU
results in the aberrant activation of the Hedgehog (Hh) pathway
(Aavikko et al., 2012).
Of all glioblastomas, the glioblastoma multiforme (GBM)
is the most aggressive form of gliomas, accounting for
approximately 50% of all glial tumors (Phillips et al., 2006). In
GBM, Notch activity is associated with the control of Glioma
Stem Cell (GSC), since its activity regulates asymmetric cell
division and Notch unbalanced expression leads to uncontrolled
growth and high malignancy (Mukherjee et al., 2016), Several
studies demonstrate a role for Notch signal in controlling growth
and stem cell maintenance of the brain also in flies (Song and Lu,
2011). Because of its conserved function, Notch pathway is now
an important target for therapeutic intervention in brain cancer
treatment (Yuan et al., 2015).
The current understanding of asymmetric cell division and
its relation to tumorigenesis is largely derived from studies
on Drosophila neuroblasts (NBs), where mutation of a single
gene, brain tumor (brat), was shown to alter asymmetric stem
cell division in larval development, and to generate massive
neoplastic growth and enlarged adult brain formed entirely of
neoplastic NBs (Caussinus and Gonzalez, 2005; Betschinger et al.,
2006). Suppression of brat expression was used to establish a
model of glioma stemness in Drosophila, where the upregulation
of Notch, induced by reducing brat, was the critical node to
maintain self-renewal and proper stemness (Mukherjee et al.,
2016). This observation was also confirmed in glioblastomas
where the human ortholog of brat, the tripartite motif-containing
protein-3 (TRIM3), was shown to be necessary to suppress
NOTCH1 signaling and to control stem cell activity during
development to reduce tumor growth (Chen et al., 2014;
Mukherjee et al., 2016). Glioma stem cells divide asymmetrically
under the guidance of cell polarity complexes that control the
proper apical and basolateral polarization and cell division, a
process that was originally identified in Drosophila and later
confirmed for the mechanism driving differentiation in human
glia for members of theHugl-1/Llgl-1 complexes (Prehoda, 2009).
We recently developed a neurogenic brain tumor model by
impairing asymmetric cell division through the loss of function
of lethal giant larvae (lgl) the Drosophila ortholog of Hugl-1,
in the type II NBs of the central brain (Paglia et al., 2017). In
our model, PI3K activation mimics PTEN loss of function and
hampers Lgl localization at the apical membrane by aPKC cortical
recruitment (Paglia et al., 2017). These data connect the function
of HUGL-1 in the maintenance of glioma stem cells with the loss
of function of the tumor suppressor PTEN (Gont et al., 2013)
and together with those in glioma (Read et al., 2009) show a
conserved function for PI3K and EGFR overexpression in these
tumors recapitulatingmany features of the neurogenic subtype of
human glioblastoma. Inhibition of PI3K/Akt activity is currently
used as a therapy in GBM (Zhao et al., 2017).
Other brain tumors such as oligodendrogliomas, that account
for 10% of all cancers of the central nervous system, are
characterized by mutations in the capicua (cic) gene (Bettegowda
et al., 2011), a conserved transcriptional repressor that regulates
MAPK effector genes downstream of receptor tyrosine kinase
(RTK) (Simon-Carrasco et al., 2018). The development of correct
animal model also for these tumors will be essential to develop
specific treatments that can tackle these different brain tumors
in vivo.
The Paradigm for Angiogenesis
In the fruit fly, the circulatory system is open, the heart
pumps the hemolymph into the body cavities and the
exchange of gases takes place directly within the organs
(Medioni et al., 2009). Moreover, Drosophila is equipped
with a complex branched system of interconnected tubules
that is responsible for the oxygen transport, the tracheal
system, an organ that is comparable in structure and
function to the circulatory system of mammals (Affolter
et al., 2009). In Drosophila’s epithelia, the induction of
clones bearing lgl, RasV12 mutations identified how tumors
are able to recruit vessels to oxygenate the growing mass
(Grifoni et al., 2015; Calleja et al., 2016). These tumor
cells showed ectopic expression of Bnl (branchless), the
Drosophila homolog of Fibroblast Growth Factors (FGFs,),
and suffered from oxygen shortage (hypoxia). In addition,
it was observed a trans-differentiation of tumor cells
into pseudo-tracheal cells with and the formation of new
vessels, mimicking human FGF-mediated vascularization in
cancer (Grifoni et al., 2015).
Cell under hypoxia condition changes their cellular
metabolism to favor growth, particularly in solid tumors (Pavlova
and Thompson, 2016; Vander Heiden and DeBerardinis, 2017).
Interesting studies in flies showed how reduction of the SCF
(Skp/Cullin/F-box)-type ubiquitin ligase Ago, homolog of
human Fbw7, increased tracheogenesis through up-regulation
of the hypoxia-inducible transcription factor Sima/dHIF and
of its target, the FGF ligand Bnl (Mortimer and Moberg,
2013). Fbw7 is known to inhibit tumor growth by targeting
proteins to the proteasome pathways, and is mutated in a
wide range of primary human cancers, this data suggests that
its role as a tumor suppressor may be conserved also in the
modulation of HIF-regulated angiogenesis in the tracheal
system of the fly (Mortimer and Moberg, 2013). This process
of neo-tracheogenesis is now considered a novel cancer
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FIGURE 3 | Cancer cells form branched and tubule-shaped structures
(reproduced from Grifoni et al., 2015) with permission). (a) An imaginal wing
disc bearing lgl4, RasV12 clones induced in a wild-type background. (b–b”)
Magnifications of the central region squared in (a). Migrating tumor cells (GFP)
are positive for the junctional marker aPKC (white) and secrete MMP1 (red).
The reconstruction along the z-axis shown in the upper part of the magnified
images reveals a tubule-shaped structure encircling a lumen, indicating these
cells are forming tracheal-like structures.
hallmark in fly, which may help to explore the relation between
angiogenesis and tumor growth in humans (Herranz et al.,
2016; Figure 3).
Lung Cancer
Lung cancer is a major cause of death in the world, and the
standard therapeutic strategy used is chemotherapy because
target therapies only decrease tumor growth and result in
high toxicity. Recently, a new Drosophila lung cancer model
was developed exploiting the tubular structure of the tracheal
network (Levine and Cagan, 2016), and considered functionally
and anatomically comparable to the vertebrate airways (Andrew
and Ewald, 2010). Both in Drosophila and mammals, airways
are formed by interconnected branches that depends on the
secretion of Bnl/FGFs by the neighboring cells (Ghabrial
et al., 2003; Grifoni et al., 2015). Using a binary system,
RasV12 was ectopically expressed specifically in the tracheal
cells while downregulating PTEN, a negative regulator of
the PI3K/AKT signaling (Hafen, 2004; Ortega-Molina and
Serrano, 2013). As a result, the cells of the tracheal branches
over-proliferated to form tumors that ultimately killed the
animals (Levine and Cagan, 2016). This model was successfully
used in a screen for chemical compounds approved by the
Food and Drug Administration (FDA), which resulted in the
identification of several compounds able to reduce cell over-
proliferation and to improve tracheal physiological functions
(Levine and Cagan, 2016), further highlighting the strong
potential of the use of fruit fly models for cancer-related
chemical screens.
Prostate and Thyroid Cancer
The prostate is an exocrine gland of the male reproductive
system responsible for the maturation and production of
the seminal fluid, with its activity depending on androgens
mostly produced by the testis. During organogenesis, the
differentiation of the prostate’s epithelium occurs along with
that of stroma and depends on the complex coordination
of many transcription factors and hormones that control
the maturation of the quiescent organ (Toivanen and Shen,
2017). The adult prostate epithelium has a low turnover
rate and its hyperplasia characterizes the majority of benign
prostatic tumors. On the contrary, adenocarcinoma of the
prostate is an aggressive tumor that rapidly progresses to a
metastatic stage that can be partially blocked by androgen
therapy (Shiao et al., 2016). Studies on flies’ male accessory
gland revealed many parallels with the physiology of human
prostate epithelium (Wilson et al., 2017), i.e., a genetic
screen using the Drosophila accessory gland identified genes
that promote growth and migration of the secondary cells
as homologs of genes expressed in human prostate cancer
(Ito et al., 2014).
Like in human prostate, Drosophila’s accessory gland presents
a secondary layer of epithelial cells that continue to proliferate;
this homology allowed the development of models that mimic
tumors of endocrine origin, including human prostate and
thyroid adenomas (Das and Cagan, 2013, 2018). For example,
the multiple endocrine neoplasia type 2 (MEN2) syndrome, is
characterized by different mutant-translocations involving the
RET genes that result in multiple cancer phenotypes, including
pheochromocytoma, parathyroid adenoma and the aggressive
medullary thyroid carcinoma (MTC) (Das and Cagan, 2013).
A recent study demonstrated that the papillary carcinoma of
the thyroid (PTC), also caused by another genomic mutations
of RET gene, can be profitably studied using the accessory
gland of Drosophila to delineate and understand the mechanisms
that characterize PTC in the context of the whole animal,
including the relationship between tumor and normal cells in an
environment that mimics tumor of endocrine origin in humans
(Levinson and Cagan, 2016).
The prostate epithelium is characterized by the abundance
of exosomes, microvesicles secreted from the endosomal
multivesicular body (MVB) that fuse with sperm to modulate its
activity and protect its homeostasis (Wilson et al., 2017). The
exosomes are particularly relevant in cancer biology for their
implication in tumor progression and survival, since they deliver
survival factors, metabolites and miRNAs, that help creating a
favorable microenvironment for cancer growth; in addition they
also favor drug-resistance by activating mechanisms that favor
the elimination of toxic chemicals such as chemotherapeutic
products (Ruivo et al., 2017; Namee and O’Driscoll, 2018).
Since the accessory gland has a similar structure as the prostate
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epithelium, characterized by the abundance of exosomes, it could
be an optimal model to better study exosome biology in tumors
of endocrine origins.
LIQUID TUMORS
The signaling pathways regulating blood cell differentiation are
conserved from Drosophila to humans (Lebestky et al., 2003;
Jung et al., 2005). In addition, fly macrophages originate via self-
renewal from progenitor cells localized in the lymph gland, a
specialized hematopoietic organ that can be compared to the
hematopoietic stem cell niche of the mammalian bone marrow
(Krzemien et al., 2007; Mandal et al., 2007). These similarities
with vertebrate hematopoiesis outline the utility of using fly
models to elucidate the basic mechanisms of hematopoietic
differentiation and homeostasis responsible for severe diseases,
including leukemia. Drosophila has already been used to study
AcuteMyeloid Leukemia (AML), a widespread form of leukemia,
and to identify the genes responsible for the disease. AML1
is a transcription factor, responsible for activating myeloid
differentiation, which has a counterpart in the fly (Sinenko
et al., 2010). In vertebrate tumors, the fusion of AML1 with the
repressor ETO inhibits the differentiation of the multilineage
progenitor cells, while their proliferation is activated, leading
to AML1. Interestingly, AML1 fused with ETO in Drosophila
also causes the inhibition of hematopoietic cell differentiation,
confirming that the fly is a good genetic model to study the
mechanisms that drive leukemia in humans (Osman et al., 2009;
Sinenko et al., 2010). Myeloproliferative neoplasms (MPNs)
have also been reproduced in the fly through gain-of-function
mutations in the JAK pathway, finding a role for the downstream
effector of the SWH pathway Yki in priming the expansion
of Drosophila blood cells, which undergo malignant behavior
following JAK activation (Anderson et al., 2017).
CANCER AND IMMUNE SYSTEM
Inflammation in tumor development acts as “tug and war”
since it may promote survival of tumor cells by favoring
angiogenesis, by reducing the natural immune responses and by
altering responses to chemotherapeutic agents (Mantovani
et al., 2008; Wu and Zhou, 2009). The inflammatory
response of cancer cells has been attributed to a response
of the immune system to eradicate the tumor, but it can
also be seen as a way to provide growth and survival, as
inflammation contributes to genomic instability by releasing
cytokines and through production of reactive oxygen species
(ROS) that may induce genetic and genomic alterations
(Negrini et al., 2010). Normal cells detect and repair DNA
damage, ensuring the maintenance of the correct number
of chromosomes and tissue homeostasis, instead often
cancer cells have increased mutation-rates leading to high
chromosomal instability (CIN) that triggers aneuploidy and
advances tumorigenesis (Negrini et al., 2010). Chromosomal
instability is a process conserved also in Drosophila, and
it was shown to contribute to the invasive behavior of
epithelial cells, with a mechanism called “compensatory
proliferation” activated to counteract CIN-induced cell death
(Clemente-Ruiz et al., 2016; Benhra et al., 2018).
The mechanisms controlling cancer immune response are
somehow conserved also in flies as studies in Drosophila have
shown that infiltration of macrophages (called hemocytes) in
cancer cells requires the activation of the JAK-STAT, JNK,
TNF-α, and Toll/Imd/TLR signaling pathways (Bangi, 2013).
Of particular interest is TNF-α that plays an important role
in controlling apoptosis and the inflammation processes (Ham
et al., 2016). TNF-α in tumors has distinct and overlapping
functions to promote tumor growth and proliferation and
to activate cell death, functions that are mainly mediated
by the activation of TNFR1 that is ubiquitously expressed
while TNFR2, mainly expressed in immune cells, is less well
understood. Thus these opposite signaling pathways activated
by TNF signals depend on the adaptor complexes recruited
by the receptors and by the cellular context, and they may
create a problem for the development of therapeutic strategies
that target TNF signaling in tumors (Ham et al., 2016). In
Drosophila the sole TNF-α, called Eiger (Egr), binds two
receptors called Wengen (Kanda et al., 2002) and Grindelwald
(Andersen et al., 2015), the latter shown necessary for the
growth of RasV12/scribble−/− tumors (Andersen et al., 2015). An
interesting mechanism links the possibility that ROS, induced
by stress or local inflammation, triggers Egr expression in the
hemocytes, to control JNK signaling, in a phenomenon called
Apoptosis-Induced Proliferation (AIP), a sort of compensatory
proliferative response of the epithelial cells that responds to
cues from local “activated” hemocytes (Fogarty et al., 2016).
Other studies highlighted the role of hemocytes in the interplay
between inflammation and cancer, i.e., using a classic cancer
model that recapitulates the hallmarks of epithelial cancer cells
(Rasv12/scribble−/−), it was shown that cancer cells induce
hemocyte’s recruitment and proliferation in vivo by activating
JNK signaling to cause the expression of JAK/STAT cytokines
(Pastor-Pareja et al., 2008). Using a similar model it was shown
that Egr expression was higher in the hemocytes derived from
cancer animals, and that its activity was necessary to stimulate
invasive migration of tumor cells (Cordero et al., 2010). On the
contrary, Egr acts as a tumor suppressor to drive apoptosis in
cancer cells upon activation of Toll/NF-κB signaling by the fat
body (adipocytes) in response to the secretion of Egr by the
circulating “activated” hemocytes (Parisi et al., 2014).Work using
allograft transplantation experiments, identify also a function
for the hemocytes in tumor initiation, that is independent on
Eiger, but relays rather on the activation by external stimuli (i.e.,
CIN, abnormal growth) of JNK pathway and on the complex
of non-autonomous and autonomous signals between tumor
cells and those composing the tumor microenvironment; a
similar mechanism has been proposed in vertebrates suggesting
a conserved response for JNK signaling in fly to control initial
tumor growth (Muzzopappa et al., 2017).
In summary, all these data suggest the existence of conserved
mechanisms between the immune and tumor cells in flies that
may recapitulate some of the most evolutionary conserved
aspects described in cancer cells.
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CANCER AND LIPID METABOLISM,
OBESITY
In tumor biology, evidences highlight the relevance of lipid
metabolism in influencing tumor growth (Katheder and Rusten,
2017; Weber et al., 2017). In this context, a recent role was
identified for adipose triglyceride lipase (ATGL) whereby it
hydrolyzes triacylglycerols into fatty acids (FAs) that may act as
signaling molecules to induce growth both cell autonomously
and in neighboring cells (Walther and Farese, 2012). The
contribution of ATGL to cancer growth is controversial, indeed
several studies showed that its depletion reduced proliferation
in colorectal cancer cells and in non-small-cell lung carcinoma
(Ou et al., 2014; Zagani et al., 2015), and in breast and pancreatic
carcinoma its upregulation contributed to tumorigenesis (Grace
et al., 2017; Wang et al., 2017). On the contrary, lack of
ATGL favored pulmonary neoplasia in mice, and in few human
tumors ATGL expression was found reduced highlighting the
complex role of lipids in tumorigenesis (Al-Zoughbi et al.,
2016). Cancer cells activate de novo lipogenesis by upregulation
of key enzymes in lipid metabolism, some of which, such as
AcetylCo-A Lyase (ACLY), AcetylCo-A Carboxylase (ACC) and
Stearoyl-CoA desaturase-1 (SCD), are targets of pharmacological
inhibitors to decrease cancer proliferation (Zaidi et al., 2012; Zu
et al., 2013; Peck and Schulze, 2016; Stoiber et al., 2018). Recent
work associated the mechanism of lypolysis with the induction
of autophagy, a mechanism used by the cells to re-cycle part
of their cytoplasm or cellular content to survive when nutrients
are reduced (Dall’Armi et al., 2013). The relevance in cancer of
the link between lipids and autophagy was shown when ATGL-
mediated lipolysis in a peritumoral area, increased autophagy and
tumor survival using a non-autonomous mechanisms (Martinez-
Outschoorn et al., 2011; Gnerlich et al., 2013). Interestingly, we
observed that Myc in Drosophila induced autophagy in the fat
body and this was enough to enhance survival of the whole
animals upon starvation (Parisi et al., 2013). We linked this
effect with the ability of Myc to increase desat1, a Stearoyl-
CoA desaturase-1 (SCD1) key enzyme in the synthesis of lipids,
that we found co-expressed with Myc in human prostatic
tumors (Paiardi et al., 2017).
Metabolic disorders and obesity are associated with
cardiovascular disease and type II diabetes (T2D), however
numerous cohort studies reported that overweight people
are more likely to develop certain types of cancer including
endometrial, breast, liver, and ovarian cancer (Cancer, 2012;
Chen et al., 2012; Riboli, 2014;Wang and Xu, 2014; Dougan et al.,
2015; Hirabayashi, 2016). Obese people have often increased
levels of circulating hormones like insulin that has been
associated to higher levels of IGF-1 in colon, kidney, prostate and
endometrial cancer (Roberts et al., 2010; Gallagher and LeRoith,
2015). Another hormone, leptin, a cytokine produced by the
adipocytes to control satiety in a signaling circuit of the brain,
has also been found up-regulated in tissues from obese people,
particularly in women post-menopause, and increased levels
of leptin have been associated with higher incidence of breast
and other tumors (Ray, 2018). The adipose tissue produces
pro-inflammatory cytokines including IL-6, IL-8, IFNγ, and
TNF-α among others (Scheller et al., 2011; Arango Duque and
Descoteaux, 2014), and their over-production in fats from obese,
activates the infiltration of macrophages into the adipose tissue
inducing a low level of chronic inflammation or adipocyte tissue
macrophage infiltration called ATM (Lafontan, 2014; Kuroda
and Sakaue, 2017). This low level of inflammation increases the
levels of ROS and induces DNA and protein damage that may
increase the risk of cancer (Lafontan, 2014; Mraz and Haluzik,
2014). The role of the inflammatory response to combat infection
and tissue injury, through the activation of the immune cells, is
conserved also in Drosophila’s circulating hemocytes (Lemaitre
and Hoffmann, 2007), where most of the signals activated in
the fat body results also in ROS production (Dionne, 2014;
Vlisidou and Wood, 2015). Indeed, we showed, using a genetic
model that harbors an inflammation state in the fat body of
larvae that mimic ATM, that reduction of ROS, using exogenous
anti-oxidants components like flavonoids and anthiocianins,
decreased hemocyte’s migration and JNK activation in the
cells of fat body (Valenza et al., 2018), suggesting that the
converging signaling between the fat body and hemocytes on
lipid metabolism and ROS/cytokines in response to stress is
conserved also in Drosophila.
CANCER STEM CELLS
Cancer stem cells (CSCs) have more features than tissue stem
cells because they are able to initiate the tumor growth and
fuel its maintenance and metastasis (Malanchi et al., 2011;
Kreso and Dick, 2014). In addition, CSCs are highly resistant
to conventional therapy, both radiation and chemotherapy, and
they are responsible for the recurrence of disease (Mueller et al.,
2009). Since the mechanisms underlying the ability of stem cells
to support cancer progression are still unclear, Drosophila is
convenient to use as it provides many tools for genetic and
molecular investigations. Adult stem cells are required for tissue
homeostasis and repair after injury and in adult flies, populations
of stem cells are present in the posterior midgut, testis, and
ovarian follicle rendering it again a good system to dissect
these stem cell programs (Hou and Singh, 2017). Drosophila
was used to better understand the functions of the centrosome
and microtubule-organizing center (MTOC) in the division of
stem cells (Tillery et al., 2018). Drosophila and mammalian stem
cells are similar and they are regulated by homologous signals
corroborating the use of the fly in this field of tumor biology.
CSCs can arise from normal stem cells whose long lifespan
favors the accumulation of genetic mutations responsible for the
malignant phenotype. The progression from normal progenitors
to stem-like cancer cells was first explored in leukemia, although
nowadays we know that several solid tumors such as brain,
breast, lung and colon cancer originate from cells with stem
features (Krivtsov et al., 2006). Several Drosophila models of
stem cell tumors are now available, and a drug screening was
successfully carried out highlighting several compounds active on
the signaling promoting cancer growth (Markstein et al., 2014).
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DROSOPHILA CANCER MODELS FOR THE
IDENTIFICATION OF
THERAPEUTIC DRUGS
Therapeutic drug discovery requires chemical screening, a
procedure allowing for the identification of potential new drugs.
The spread of sequencing, automation, and miniaturization has
made High Throughput Screening (HTS) the leading contributor
to early-stage drug discovery. HTS consists of random screening
of chemicals to find an affinity for a specific protein or biological
activity characteristic of a disorder. Once identified in vitro, the
compounds need to be validated in vivo to assess efficacy and
toxicity during a long and expensive period of drug development.
The high throughput assays depend on the existence of a specific
target, assuming an in depth understanding of a disease that is
not always available. Phenotype screening is an eligible option
when the knowledge about the mechanisms underlying a disease
process is not well defined. It is a process by which small
molecules are screened for their effect on the phenotype in cells,
tissue or whole animals, where a more physiological environment
better describes the pharmacokinetics and toxicological effects of
a drug. The great availability of genetic tools and the low cost
of maintenance makes the fruit fly an ideal to model to study
human diseases including cancer, in fact the fly has considerably
contributed to understand tumor biology.
Chemical screens have been successfully performed in
Drosophila for several disorders affecting the central nervous
system, kidney and metabolism (Whitworth et al., 2006; Gasque
et al., 2013; Hofherr et al., 2016), as well as for a type of thyroid
cancer, the multiple endocrine neoplasia type 2A and 2B (MEN2)
(Vidal et al., 2005). Regarding cancer, JAK- STAT, APC, Wnt,
Notch and other signaling molecules, deeply characterized in
Drosophila and shared with humans, are precious for cancer drug
development. The availability of Drosophila models for multiple
cancer types makes pharmacological screens possible against
several drugs that aim to restrict proliferation and metastasis.
The identification of anticancer compounds is possible using
the adult fly, but also larvae, embryos and cells. The combined
effect of anti-cancer drugs with radiation has been investigated in
Drosophila larvae, producing similar findings to those observed
in human cancer cells (Edwards et al., 2011). Moreover,
Drosophila avatars, consisting of patient-specific tumors modeled
in transgenic flies, are very promising for personalized medicine.
Drosophila and other small model organisms are helpful to
quickly analyze the mode of action of several active compounds
in vivo, nevertheless mammalian models are indispensable in
the successive phase of drug development to define important
pharmacokinetic parameters such as absorption, distribution
and metabolism.
DISCUSSION
The communication between tumor cells and their
microenvironment is largely implicated in neoplastic growth,
hence the substantial difficulty to recapitulate the features of
malignant transformation in cellular systems. Cancer research
needs in vivo investigations, and the use of model organisms
contributes to answer this request. In this review we described
most relevant approaches in Drosophila, used to explore
cancer mechanisms and therapeutics that contribute to our
understanding on tumor initiation and progression. In spite of
some limitations, because of the anatomical differences between
flies and humans, the use of Drosophila’s cancer models has been
fundamental to understand some basic processes that regulate
human cancers, such as the competitiveness of cancer stem cells
(CSCs), the importance of tumor microenvironment, cancer
cachexia, drug resistance and tumor-associated vasculogenesis,
which was recently found to be functionally conserved in fly’s
cancer. Additional cancer hallmarks such as genomic instability,
resistance to cell death, cell metabolism reprogramming, tumor-
promoting inflammation and evasion from the immune system,
have been studied and extensively characterized in Drosophila.
Finally, although the evolutionary difference between Drosophila
and humans certainly represents a restriction to the use of
the fruit fly in drug discovery and development, phenotypic
screenings have proven relevant to identify potential drugs
that would elude the classic screens in the absence of targets.
Drosophila is also offering a significant contribution to the
investigation of organotypic cancers, since despite the evident
differences at the macroscopic level, organ cells and functional
units are usually well conserved at the biochemical and structural
levels respectively. This conservation allowed to develop thyroid,
lung, prostate, gut, brain and blood cancer models starting
from the most characteristic genetic lesions found in the same
human cancers. These models, as described in the review,
are greatly helping in dissecting the contribution of specific
molecular pathways to the final cancer phenotype. Given
the heterogeneous nature of mammalian solid cancers, new
strategies are being developed to decipher cancers at single-
cell resolution. The international Drosophila community has
always been engaged in the development of novel, sophisticated
genetic tools, which allowed in the last 30 years to revolutionate
functional gene analysis. For this reason, we anticipate that
the use of the fruit fly will move fast into the field of precision
medicine, contributing to seminal findings in this new era of
cancer research.
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